ADCT
ADC Therapeutics SANYSEHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$431.18M
P/E Ratio
—
EPS
$-0.97
Beta
1.84
52W High
$4.98
52W Low
$2.25
50-Day MA
$3.79
200-Day MA
$3.81
Dividend Yield
—
Profit Margin
-173.00%
Forward P/E
—
PEG Ratio
—
About ADC Therapeutics SA
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Fundamentals
| Revenue (TTM) | $79.17M |
| Gross Profit (TTM) | $-20.85M |
| EBITDA | $-102.04M |
| Operating Margin | -121.10% |
| Return on Equity | -706.00% |
| Return on Assets | -22.70% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $-1.70 |
| Price-to-Book | 3.42 |
| Price-to-Sales (TTM) | 5.45 |
| EV/Revenue | 4.002 |
| EV/EBITDA | -1.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -9.50% |
| Shares Outstanding | $127.19M |
| Float | $100.41M |
| % Insiders | 13.25% |
| % Institutions | 67.61% |
Historical Volatility
HV 10-Day
43.36%
HV 20-Day
46.64%
HV 30-Day
55.88%
HV 60-Day
60.89%
HV Rank
20.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($8.20 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026